SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PROTEOMICS -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (139)10/17/2000 9:06:23 AM
From: scaram(o)uche  Respond to of 539
 
Novartis continues to invest aggressively in the future. It goes on and on and they look better and better, IMO.



To: nigel bates who wrote (139)11/20/2000 5:55:13 PM
From: nigel bates  Read Replies (1) | Respond to of 539
 
Something I missed from Proteome Science's half year report in June -
Proteome Sciences is a founder shareholder in GeneProtTM, a company formed in March this year to sequence the human proteome....
They must have been diluted significantly in the last funding round ($40m in July) and the deals with Novartis and Bruker Daltronics -
Message 14595152
Message 14374179
- but it's something I hadn't factored in at all.

nig


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News